Apalutamide in Patients with Metastatic Castration-Sensitive Prostate Cancer (TITAN Study)
Source: View publication →
In the phase 3 TITAN trial, the addition of apalutamide to androgen-deprivation therapy (ADT) significantly improved overall survival and radiographic progression-free survival in a broad population of patients with metastatic castration-sensitive prostate cancer.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TITAN trial provides robust evidence supporting the use of apalutamide in combination with ADT as an effective first-line treatment for a broad population of patients with mCSPC, including those with both high- and low-volume disease, regardless of prior systemic therapy for localized disease.
Historical Context
The TITAN trial, published in 2019, followed established data showing that adding second-generation antiandrogens or chemotherapy to ADT improves survival in mCSPC. It expanded the therapeutic options by demonstrating efficacy in a more heterogeneous patient population than previous landmark trials like CHAARTED or LATITUDE.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of apalutamide differ from first-generation antiandrogens like bicalutamide, and why is this significant in the treatment of metastatic castration-sensitive prostate cancer (mCSPC)?
Key Response
Apalutamide is a next-generation androgen receptor (AR) inhibitor. Unlike first-generation agents like bicalutamide, which only compete for ligand binding, apalutamide also inhibits AR nuclear translocation and AR-mediated DNA binding. This more potent inhibition is crucial in mCSPC because it overcomes common resistance mechanisms seen in first-generation drugs, where the receptor can occasionally act as an agonist in the setting of rising AR expression levels.
In a patient newly diagnosed with metastatic castration-sensitive prostate cancer, what factors would lead you to choose the TITAN regimen (Apalutamide + ADT) over the CHAARTED regimen (Docetaxel + ADT)?
Key Response
The choice involves balancing volume of disease, fitness, and toxicity. While docetaxel (CHAARTED) showed primary benefit in high-volume disease and carries risks of myelosuppression and neuropathy, apalutamide (TITAN) showed benefit in both high- and low-volume disease. Apalutamide is generally preferred for patients seeking to avoid chemotherapy or those with low-volume disease, though clinicians must monitor for specific side effects like skin rash and hypothyroidism.
The TITAN trial included a subset of patients who received prior docetaxel. How should the survival benefit observed in this subgroup inform the clinical adoption of 'triplet therapy' (ADT + Docetaxel + ARPI) in modern uro-oncology?
Key Response
TITAN demonstrated that adding apalutamide improved outcomes even in those with prior docetaxel exposure (hazard ratio for death 0.66). This provided early evidence that intensifying therapy beyond ADT+Docetaxel was beneficial. This has been further validated by trials like PEACE-1 and ARASENS, establishing triplet therapy as a standard of care for patients with high-volume mCSPC who are fit for chemotherapy.
Considering the long-term results of the TITAN study, how do you manage the 27% incidence of skin rash and the increased risk of fractures in patients on apalutamide compared to other AR signaling inhibitors?
Key Response
Management of apalutamide-specific toxicities is key for adherence. The rash is typically maculopapular and often resolves with topical steroids or temporary dose interruption/reduction. Fracture risk (reported at roughly 9% vs 3% in placebo) necessitates baseline and periodic bone mineral density (BMD) scans and the early introduction of bone-protective agents (bisphosphonates or denosumab) alongside calcium and Vitamin D, which is a critical teaching point for managing long-term survivors.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TITAN trial utilized a dual primary endpoint of radiographic progression-free survival (rPFS) and overall survival (OS). What are the statistical implications of this design regarding alpha-spending, and what are the limitations of rPFS as a surrogate for OS in the castration-sensitive setting?
Key Response
Using dual primary endpoints requires the pre-specification of alpha-splitting to control the family-wise type I error rate. In TITAN, alpha was partitioned (e.g., 0.005 for rPFS and 0.045 for OS). While rPFS is a validated surrogate in mCRPC, its correlation with OS in mCSPC is weaker due to the longer duration of subsequent lines of therapy, which can dilute the OS signal, making the achievement of a statistically significant OS benefit in TITAN particularly robust.
Following the primary analysis of TITAN, the trial was unblinded and approximately 40% of the placebo group crossed over to the apalutamide arm. As a reviewer, how would you evaluate the impact of this crossover on the final OS hazard ratio, and which statistical models would you require the authors to use to address this?
Key Response
Crossover can lead to an underestimation of the true survival benefit (Type II error). To maintain methodological rigor, an editor would expect the authors to perform sensitivity analyses such as the Rank Preserving Structural Failure Time (RPSFT) model or Inverse Probability of Censoring Weighting (IPCW). These models estimate the treatment effect as if the crossover had not occurred, ensuring the reported efficacy is not confounded by the ethical necessity of unblinding.
Given that TITAN demonstrated benefit across both high- and low-volume mCSPC, should current guidelines (NCCN or EAU) prioritize ARPIs over docetaxel for low-volume disease, and what is the strength of this recommendation?
Key Response
Current NCCN and EAU guidelines have been updated to reflect TITAN results, giving a Category 1 (Strong) recommendation for adding an ARPI (apalutamide, enzalutamide, or abiraterone) to ADT for mCSPC regardless of volume. Because docetaxel showed no significant OS benefit in low-volume disease (per CHAARTED/STAMPEDE long-term data), guidelines now explicitly favor ARPIs for low-volume patients, whereas for high-volume patients, both ARPIs and triplets are viable options.
Clinical Landscape
Noteworthy Related Trials
CHAARTED Trial
Tested
Docetaxel plus Androgen Deprivation Therapy (ADT)
Population
Metastatic castration-sensitive prostate cancer
Comparator
ADT alone
Endpoint
Overall survival
LATITUDE Trial
Tested
Abiraterone acetate plus prednisone with ADT
Population
High-risk metastatic castration-sensitive prostate cancer
Comparator
ADT plus dual placebos
Endpoint
Overall survival and radiographic progression-free survival
ARCHES Trial
Tested
Enzalutamide plus ADT
Population
Metastatic castration-sensitive prostate cancer
Comparator
ADT plus placebo
Endpoint
Radiographic progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis